News

FOX40 News1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - FOX40
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
Clinical Trials Arena on MSN3d
Parkinson’s drug found to be effective in treating depression
Despite a significant improvement in symptoms, around 20% of patients discontinued treatment due to adverse events.
Medscape7d
Bromocriptine: A Dopamine Agonist for the Treatment of Diabetes - Medscape
Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h ...
Morningstar1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - Morningstar
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025.
WAVY-TV1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - WAVY.com
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
KELOLAND News1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the ... - KELOLAND.com
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
KOLR10 & Ozarks Local News1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - KOLR
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
WWLP-22News1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - WWLP
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
KOIN 61mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - KOIN.com
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
Mena FN1mon
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL ... - MENAFN.COM
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025. Date.
KXAN1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL ... - KXAN Austin
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from ...
The Victoria Advocate1mon
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at ... - Victoria Advocate
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Skip to main content. You have permission to edit this ...